Yifan Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Yifan Pharmaceutical has a total shareholder equity of CN¥8.3B and total debt of CN¥2.0B, which brings its debt-to-equity ratio to 23.4%. Its total assets and total liabilities are CN¥11.8B and CN¥3.4B respectively. Yifan Pharmaceutical's EBIT is CN¥91.7M making its interest coverage ratio 1.5. It has cash and short-term investments of CN¥835.6M.
Key information
23.4%
Debt to equity ratio
CN¥1.95b
Debt
| Interest coverage ratio | 1.5x |
| Cash | CN¥835.56m |
| Equity | CN¥8.35b |
| Total liabilities | CN¥3.43b |
| Total assets | CN¥11.78b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 002019's short term assets (CN¥3.5B) exceed its short term liabilities (CN¥2.5B).
Long Term Liabilities: 002019's short term assets (CN¥3.5B) exceed its long term liabilities (CN¥954.8M).
Debt to Equity History and Analysis
Debt Level: 002019's net debt to equity ratio (13.4%) is considered satisfactory.
Reducing Debt: 002019's debt to equity ratio has increased from 21.7% to 23.4% over the past 5 years.
Debt Coverage: 002019's debt is well covered by operating cash flow (27%).
Interest Coverage: 002019's interest payments on its debt are not well covered by EBIT (1.5x coverage).